KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fulgent Genetics (FLGT) EBT (2016 - 2025)

Historic EBT for Fulgent Genetics (FLGT) over the last 11 years, with Q3 2025 value amounting to -$7.5 million.

  • Fulgent Genetics' EBT rose 5948.09% to -$7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.8 million, marking a year-over-year increase of 7419.77%. This contributed to the annual value of -$52.0 million for FY2024, which is 7015.48% up from last year.
  • Latest data reveals that Fulgent Genetics reported EBT of -$7.5 million as of Q3 2025, which was up 5948.09% from -$21.5 million recorded in Q2 2025.
  • In the past 5 years, Fulgent Genetics' EBT ranged from a high of $267.2 million in Q1 2021 and a low of -$145.2 million during Q4 2023
  • Moreover, its 5-year median value for EBT was -$8.0 million (2024), whereas its average is $31.3 million.
  • Its EBT has fluctuated over the past 5 years, first surged by 1607154.81% in 2021, then tumbled by 37014.58% in 2024.
  • Over the past 5 years, Fulgent Genetics' EBT (Quarter) stood at $150.8 million in 2021, then tumbled by 122.19% to -$33.5 million in 2022, then plummeted by 333.91% to -$145.2 million in 2023, then skyrocketed by 94.46% to -$8.0 million in 2024, then grew by 6.66% to -$7.5 million in 2025.
  • Its last three reported values are -$7.5 million in Q3 2025, -$21.5 million for Q2 2025, and -$11.7 million during Q1 2025.